Izalontamab |
SI-B001; SI-1X6.4 |
Phase 3 Clinical |
|
Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Izalontamab brengitecan |
BL-B01D1 |
Phase 3 Clinical |
SystImmune |
Nasopharyngeal Carcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Solid tumours; Digestive System Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms, Fibroepithelial |
Details
|
Nezutatug |
HMBD-001 |
Phase 2 Clinical |
Hummingbird Bioscience |
Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Uterine Cervical Neoplasms |
Details
|
Sapitinib |
AZD-8931 |
Phase 2 Clinical |
Astrazeneca Plc |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
Seribantumab |
MM-121; SAR-256212; 1N3L70MDFX (UNII code) |
Phase 2 Clinical |
Merrimack Pharmaceuticals Inc |
Prostatic Neoplasms; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lung Neoplasms; Gallbladder Neoplasms; Uterine Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Sarcoma; Cholangiocarcinoma; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Kidney Neoplasms; Solid tumours |
Details
|
Tesevatinib |
XL-647; KD-020; KD-019; EXEL-7647 |
Phase 2 Clinical |
Exelixis Inc |
Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase 2 Clinical |
Shanghai Allist Pharmaceutical Technology Co Ltd |
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Zenocutuzumab |
MCLA-128 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
89Zr-Patritumab deruxtecan |
|
Phase 2 Clinical |
Daiichi Sankyo Co Ltd, The Netherlands Cancer Institute, Daiichi Sankyo Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
IBI-133 |
IBI133; IBI-133 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
DB-1310 |
DB-1310 |
Phase 2 Clinical |
|
Solid tumours; Neoplasm Metastasis |
Details
|
SIBP-03 |
SIBP-03 |
Phase 2 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Squamous Cell Carcinoma of Head and Neck; Neoplasms |
Details
|
SHR-A2009 |
SHR-A2009 |
Phase 2 Clinical |
Suzhou Suncadia Biopharmaceuticals Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) |
JK07; SAL-007 |
Phase 2 Clinical |
Shenzhen Salubris Pharmaceuticals Co Ltd |
Heart Failure |
Details
|
Elgemtumab |
NOV-6; LJM-716 |
Phase 1 Clinical |
Novartis Pharma Ag, Morphosys Ag |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma |
Details
|
MP-0274 |
DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 |
Phase 1 Clinical |
Molecular Partners Ag |
Neoplasms |
Details
|
AV-203 |
AV-203; CAN-017 |
Phase 1 Clinical |
Aveo |
Solid tumours; Neoplasms |
Details
|
Barecetamab |
ISU-104 |
Phase 1 Clinical |
Isu Abxis Co Ltd |
Solid tumours |
Details
|
Sirotinib Maleate |
XZP-5491 |
Phase 1 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
SYS-6023 |
SYS-6023; SYS6023 |
Phase 1 Clinical |
Jushi Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
AMT-562 |
AMT-562 |
Phase 1 Clinical |
Multitude Therapeutics Inc |
Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
SIBP-A13 |
SIBP-A13 |
Phase 1 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Head and Neck Neoplasms; Solid tumours; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant human ErbB3 fragment vaccine (Zensun) |
rhErbB3-f |
Phase 1 Clinical |
Zensun (Shanghai) Sci&Tech Co Ltd |
Neoplasms |
Details
|
Recombinat humanized HER3-targeting antibody |
|
Phase 1 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Solid tumours |
Details
|